Targeting transcription factors in multiple myeloma: evolving therapeutic strategies

Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments

(2018) Jingping Hu et al.   CANCER LETTERS

Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation

(2018) Ailing Liu et al.   HAEMATOLOGICA

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

(2018) Shaji K. Kumar et al.   Journal of the National Comprehensive Cancer Network

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

(2018) Noopur Raje et al.   LANCET ONCOLOGY

Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma

(2018) Xiaohui Zhang et al.   LEUKEMIA

Targeting MYC in multiple myeloma

(2018) K. K. Jovanović et al.   LEUKEMIA

NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways

(2018) Ayumi Honda et al.   Blood Cancer Journal

Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation

(2018) Ailing Liu et al.   HAEMATOLOGICA

IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38

(2018) Pasquale L. Fedele et al.   BLOOD

DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling

(2018) Kazuya Ishiguro et al.   HAEMATOLOGICA

Bortezomib Targets Sp Transcription Factors in Cancer Cells

(2018) Keshav Karki et al.   MOLECULAR PHARMACOLOGY

The biological significance of histone modifiers in multiple myeloma: clinical applications

(2018) Hiroto Ohguchi et al.   Blood Cancer Journal

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma

(2018) Ajay K. Nooka et al.   JAMA Oncology

Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis

(2018) Daniela N Petrusca et al.   Journal of Hematology & Oncology

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

(2018) Mariateresa Fulciniti et al.   Cell Reports

Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription

(2017) Kenia Ubieta et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

(2017) William McCoull et al.   JOURNAL OF MEDICINAL CHEMISTRY

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival

(2017) H Ohguchi et al.   LEUKEMIA

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma

(2017) J Bae et al.   LEUKEMIA

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

(2017) A Gullà et al.   LEUKEMIA

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast Differentiation

(2017) Juraj Adamik et al.   MOLECULAR CANCER RESEARCH

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

(2017) Loren M. Lasko et al.   NATURE

Functions of bromodomain-containing proteins and their roles in homeostasis and cancer

(2017) Takao Fujisawa et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4

(2017) N Ueno et al.   ONCOGENE

Logic programming reveals alteration of key transcription factors in multiple myeloma

(2017) Bertrand Miannay et al.   Scientific Reports

Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells

(2016) Shinya Endo et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting transcription factors by small compounds—Current strategies and future implications

(2016) Judith Hagenbuchner et al.   BIOCHEMICAL PHARMACOLOGY

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma

(2016) Y.-W. Qiang et al.   BLOOD

Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells

(2016) K-H Hung et al.   CELL DEATH AND DIFFERENTIATION

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

(2016) C. Pawlyn et al.   CLINICAL CANCER RESEARCH

3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 signaling through the induction of PIAS3

(2016) Jeong-Hyeon Ko et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside

(2016) Takeshi Harada et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

(2016) F Fan et al.   LEUKEMIA

Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma

(2016) K T Siu et al.   LEUKEMIA

Differentiation stage of myeloma plasma cells: biological and clinical significance

(2016) B Paiva et al.   LEUKEMIA

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma

(2016) Nicola Amodio et al.   MOLECULAR CANCER THERAPEUTICS

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression

(2016) Andrew P. Feinberg et al.   NATURE REVIEWS GENETICS

The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival

(2016) Hiroto Ohguchi et al.   Nature Communications

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

(2015) Michele Cea et al.   BLOOD

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death

(2015) Yuko Mishima et al.   BRITISH JOURNAL OF HAEMATOLOGY

Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma

(2015) P. Maiso et al.   CANCER RESEARCH

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma

(2015) Megan Y Murray et al.   CELL CYCLE

The RUNX1–PU.1 axis in the control of hematopoiesis

(2015) Maria Rosaria Imperato et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Advances in the pathogenesis and diagnosis of multiple myeloma

(2015) M. Chesi et al.   International Journal of Laboratory Hematology

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

(2015) E Morelli et al.   LEUKEMIA

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

(2015) S Kikuchi et al.   LEUKEMIA

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

(2015) Brian A. Walker et al.   Nature Communications

Transcriptional repression by the HDAC4–RelB–p52 complex regulates multiple myeloma survival and growth

(2015) Subrahmanya D. Vallabhapurapu et al.   Nature Communications

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

(2015) Matthew B. Siegel et al.   Oncotarget

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma

(2015) Enrica Borsi et al.   Oncotarget

MYC regulates the non-coding transcriptome

(2015) Jonathan R. Hart et al.   Oncotarget

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

(2014) Y. X. Zhu et al.   BLOOD

The AP-1 transcription factor Fra1 inhibits follicular B cell differentiation into plasma cells

(2014) Bettina Grötsch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

(2014) M Affer et al.   LEUKEMIA

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target

(2014) N I Herath et al.   Blood Cancer Journal

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma

(2013) M. F. Kaiser et al.   BLOOD

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762

(2013) A. Chaidos et al.   BLOOD

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

(2013) Nicola Amodio et al.   CELL CYCLE

Repression of the Transcription Factor Bach2 Contributes to Predisposition of IgG1 Memory B Cells toward Plasma Cell Differentiation

(2013) Kohei Kometani et al.   IMMUNITY

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

(2013) Jesús F. San-Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting p53 by small molecules in hematological malignancies

(2013) Manujendra N Saha et al.   Journal of Hematology & Oncology

Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis

(2013) C. J. Heuck et al.   JOURNAL OF IMMUNOLOGY

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

(2013) J Minami et al.   LEUKEMIA

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction

(2013) P Storti et al.   LEUKEMIA

From genetic variation to phenotype via chromatin

(2013) Hannah Stower   NATURE REVIEWS GENETICS

Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors

(2013) Eléonore Otjacques et al.   PLoS One

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases

(2013) F Hayakawa et al.   Blood Cancer Journal

Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation

(2012) G. Xu et al.   BLOOD

Addiction to c-MYC in multiple myeloma

(2012) T. Holien et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Blockade of XBP1 splicing by inhibition of IRE1  is a promising therapeutic option in multiple myeloma

(2012) N. Mimura et al.   BLOOD

SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

(2012) L López-Corral et al.   LEUKEMIA

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers

(2012) Dinis Pedro Calado et al.   NATURE IMMUNOLOGY

IMiD immunomodulatory compounds block C/EBP  translation through eIF4E down-regulation resulting in inhibition of MM

(2011) S. Li et al.   BLOOD

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

(2011) S. D'Souza et al.   BLOOD

The Pax-5 Gene: A Pluripotent Regulator of B-cell Differentiation and Cancer Disease

(2011) P. O'Brien et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

(2011) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

(2010) T. Bagratuni et al.   BLOOD

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

(2010) T. Hideshima et al.   BLOOD

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

(2010) C. M. Annunziata et al.   BLOOD

Overexpression of PAX5 induces apoptosis in multiple myeloma cells

(2010) Maryse Proulx et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

(2010) A Scuto et al.   LEUKEMIA

Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation

(2010) Shane Crotty et al.   NATURE IMMUNOLOGY

DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance

(2009) Carmen Stanganelli et al.   ANNALS OF HEMATOLOGY

Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)

(2009) E F Wagner   ANNALS OF THE RHEUMATIC DISEASES

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

(2009) R. Pal et al.   BLOOD

C/EBP  regulates transcription factors critical for proliferation and survival of multiple myeloma cells

(2009) R. Pal et al.   BLOOD

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1 -Dependent Pathway in Multiple Myeloma

(2009) J. Zhang et al.   CANCER RESEARCH

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

Sp1 Phosphorylation and Its Regulation of Gene Transcription

(2009) N. Y. Tan et al.   MOLECULAR AND CELLULAR BIOLOGY

A census of human transcription factors: function, expression and evolution

(2009) Juan M. Vaquerizas et al.   NATURE REVIEWS GENETICS

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

(2008) E. A. Nelson et al.   BLOOD

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE